AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36156704 — intervention group
Group type: EXPERIMENTAL
Intervention: Conscious Sedation (CS)
Number of subjects: 87
Study 36156704 — intervention group
Group type: COMPARATOR
Intervention: General Anesthesia (GA)
Number of subjects: 87
Study 32901094 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline anxiety levels measured using the MAX‐PC questionnaire.
Number of subjects: 302
Study 32901094 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage of positive biopsy cores.
Number of subjects: 302
Study 32901094 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline anxiety levels.
Number of subjects: 302
Study 32727509 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended training condition (prolonged exposure workshop followed by 6-8 months of post-workshop expert case consultation)
Number of subjects: 103
Study 32727509 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended training condition
Number of subjects: 103
Study 32727509 — intervention group
Group type: COMPARATOR
Intervention: Standard training condition
Number of subjects: 103
Study 35588357 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus breathing exercises (UC+BrEX)
Number of subjects: 193
Study 35588357 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 193
Study 32723512 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic hand-held pulsed vibration device
Number of subjects: 166
Study 32723512 — intervention group
Group type: COMPARATOR
Intervention: Topical anaesthesia
Number of subjects: 166
Study 36250307 — intervention group
Group type: EXPERIMENTAL
Intervention: ACURATE neo2
Number of subjects: 1356
Study 36250307 — intervention group
Group type: COMPARATOR
Intervention: SAPIEN 3 Ultra
Number of subjects: 1356
Study 33507363 — intervention group
Group type: EXPERIMENTAL
Intervention: rIPC + Exercise
Number of subjects: 19
Study 33507363 — intervention group
Group type: COMPARATOR
Intervention: rIPC only
Number of subjects: 19
Study 36219590 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipyretics + warm compresses
Number of subjects: 33
Study 36219590 — intervention group
Group type: COMPARATOR
Intervention: Antipyretics
Number of subjects: 33
Study 33145944 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 5 mg
Number of subjects: 530
Study 33145944 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Number of subjects: 530
Study 33145944 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 530
Study 32629403 — intervention group
Group type: EXPERIMENTAL
Intervention: Monomethyl fumarate (MMF) 190 mg
Number of subjects: 100
Study 32629403 — intervention group
Group type: COMPARATOR
Intervention: Dimethyl fumarate (DMF) 240 mg
Number of subjects: 100
Study 34046894 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive ultrasound-guided carpal tunnel release (USCTR)
Number of subjects: 89
Study 34046894 — intervention group
Group type: COMPARATOR
Intervention: Open carpal tunnel release (OCTR)
Number of subjects: 89
Study 33180376 — intervention group
Group type: EXPERIMENTAL
Intervention: ICS/LABA/LAMA (HFA-BDP + olodaterol 5 µg/tiotropium 5 µg)
Number of subjects: 16
Study 33180376 — intervention group
Group type: COMPARATOR
Intervention: ICS/LABA (HFA-BDP + olodaterol 5 µg)
Number of subjects: 16
Study 36333954 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic Acid (5 mg intravenously)
Number of subjects: 76
Study 36333954 — intervention group
Group type: COMPARATOR
Intervention: Denosumab and Teriparatide (20-μg or 40-μg daily)
Number of subjects: 76
Study 33476973 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 147
Study 33476973 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine + Alprazolam
Number of subjects: 147
Study 33476973 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study 32725695 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction (BFR) treatment
Number of subjects: 10
Study 32725695 — intervention group
Group type: COMPARATOR
Intervention: Control group (no BFR treatment)
Number of subjects: 10
Study 36123593 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight glucose control (80–110 mg/dl) using LOGIC-Insulin software
Number of subjects: 9230
Study 36123593 — intervention group
Group type: COMPARATOR
Intervention: Liberal glucose control (targeting 180–215 mg/dl, initiating insulin only when hyperglycemia >215 mg/dl)
Number of subjects: 9230
Study 34198888 — intervention group
Group type: EXPERIMENTAL
Intervention: Palm Stearin (PS)
Number of subjects: 24
Study 34198888 — intervention group
Group type: COMPARATOR
Intervention: Butter
Number of subjects: 24
Study 35559993 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 μM cFEE
Number of subjects: 1629
Study 35559993 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 μM cFEE
Number of subjects: 1629
Study 35559993 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1629
Study 35559993 — intervention group
Group type: EXPERIMENTAL
Intervention: cFEE (1 μM and 100 μM)
Number of subjects: 1629
Study 33297893 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous argatroban (100 µg/kg bolus followed by 3 µg/kg/min for 12 h)
Number of subjects: 1200
Study 33297893 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous eptifibatide (135 µg/kg bolus followed by 0.75 µg/kg/min infusion for 2 h)
Number of subjects: 1200
Study 33297893 — intervention group
Group type: COMPARATOR
Intervention: IV placebo
Number of subjects: 1200
Study 34304609 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative new or newly enlarging T2 lesions at 96 weeks
Number of subjects: 889
Study 34304609 — intervention group
Group type: EXPERIMENTAL
Intervention: Normalized brain volume loss at 48 weeks
Number of subjects: 889
Study 34304609 — intervention group
Group type: COMPARATOR
Intervention: MRI measures
Number of subjects: 889
Study 32149759 — intervention group
Group type: COMPARATOR
Intervention: Carbetocin 50 µg (C50)
Number of subjects: 50
Study 32149759 — intervention group
Group type: COMPARATOR
Intervention: Carbetocin 100 µg (C100)
Number of subjects: 50
Study 32149759 — intervention group
Group type: COMPARATOR
Intervention: Control (no carbetocin)
Number of subjects: 50
Study 33807703 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice meal group (RMG)
Number of subjects: 105
Study 33049909 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-Based REDUCE Intervention Program
Number of subjects: 122
Study 33049909 — intervention group
Group type: COMPARATOR
Intervention: Wait-list group (Control)
Number of subjects: 122
Study 35837833 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin (0.25 mg)
Number of subjects: 10
Study 36086927 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcision plus Stromal-Vascular Fraction (SVF)
Number of subjects: 10
Study 36086927 — intervention group
Group type: COMPARATOR
Intervention: Subcision alone
Number of subjects: 10
Study 33203385 — intervention group
Group type: EXPERIMENTAL
Intervention: CAMP (summer day camp)
Number of subjects: 94
Study 33203385 — intervention group
Group type: COMPARATOR
Intervention: SAU (unstructured summer as usual)
Number of subjects: 94
Study 33402403 — intervention group
Group type: COMPARATOR
Intervention: Coenzyme Q10 (CoQ10) supplementation
Number of subjects: 371
Study 32460511 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-low-dose (ULD) protocol (axial scan)
Number of subjects: 97
Study 32460511 — intervention group
Group type: COMPARATOR
Intervention: Conventional helical mode (Group B)
Number of subjects: 97
Study 32618255 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass drug administration and standard of care package (including improved surveillance, increased access to malaria case management, and sustained high levels of vector control coverage)
Number of subjects: 1620
Study 32618255 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass drug administration and standard of care package
Number of subjects: 1620
Study 35325239 — intervention group
Group type: EXPERIMENTAL
Intervention: Flora imagery
Number of subjects: 2000
Study 35325239 — intervention group
Group type: EXPERIMENTAL
Intervention: Sweepstakes
Number of subjects: 2000
Study 35325239 — intervention group
Group type: EXPERIMENTAL
Intervention: Eco-friendly language
Number of subjects: 2000
Study 35325239 — intervention group
Group type: EXPERIMENTAL
Intervention: Sweepstakes interaction
Number of subjects: 2000
Study 32350413 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential nab-paclitaxel plus gemcitabine (SEQ)
Number of subjects: 146
Study 32350413 — intervention group
Group type: COMPARATOR
Intervention: Concomitant nab-paclitaxel plus gemcitabine (CON)
Number of subjects: 146
Study 35861827 — intervention group
Group type: EXPERIMENTAL
Intervention: Avocado Supplemented
Number of subjects: 1008
Study 35861827 — intervention group
Group type: COMPARATOR
Intervention: Habitual Diet
Number of subjects: 1008
Study 34506822 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Training (ET)
Number of subjects: 24
Study 34506822 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 24
Study 34894449 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal theophylline saline irrigation (twice a day for 6 weeks)
Number of subjects: 22
Study 34894449 — intervention group
Group type: COMPARATOR
Intervention: Placebo saline irrigation (twice a day for 6 weeks)
Number of subjects: 22
Study 34894449 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal theophylline saline irrigation
Number of subjects: 22
Study 34894449 — intervention group
Group type: COMPARATOR
Intervention: Placebo saline irrigation
Number of subjects: 22
Study 34406329 — intervention group
Group type: EXPERIMENTAL
Intervention: Office-based vergence accommodative therapy (OBVAT)
Number of subjects: 100
Study 34406329 — intervention group
Group type: COMPARATOR
Intervention: Office-based placebo therapy (OBPT)
Number of subjects: 100
Study 32925744 — intervention group
Group type: EXPERIMENTAL
Intervention: MDL‐SHPVP (multidisciplinary team-led school-based HPV vaccination health-promotion program)
Number of subjects: 2520
Study 34824710 — intervention group
Group type: EXPERIMENTAL
Intervention: Adductor Canal Block (ACB) alone (30 ml of 0.2% ropivacaine)
Number of subjects: 150
Study 34824710 — intervention group
Group type: EXPERIMENTAL
Intervention: Periarticular Local Infiltration (PLI) alone (30 ml 0.5% ropivacaine in 20 ml of normal saline)
Number of subjects: 150
Study 34824710 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined ACB and PLI
Number of subjects: 150
Study 34824710 — intervention group
Group type: COMPARATOR
Intervention: Control group (ACB alone or PLI alone)
Number of subjects: 150
Study 32003492 — intervention group
Group type: EXPERIMENTAL
Intervention: Stratified trials
Number of subjects: 0
Study 32003492 — intervention group
Group type: COMPARATOR
Intervention: Unstratified trials
Number of subjects: 0
Study 34021607 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg biperiden
Number of subjects: 12
Study 34021607 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 32611602 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse oximeter sensor with opaque wrap
Number of subjects: 96
Study 32611602 — intervention group
Group type: COMPARATOR
Intervention: Pulse oximeter sensor without opaque wrap
Number of subjects: 96
Study 32611602 — intervention group
Group type: EXPERIMENTAL
Intervention: Masimo sensor
Number of subjects: 96
Study 32611602 — intervention group
Group type: COMPARATOR
Intervention: Nellcor sensor
Number of subjects: 96
Study 32611602 — intervention group
Group type: EXPERIMENTAL
Intervention: Babies receiving phototherapy
Number of subjects: 96
Study 32777617 — intervention group
Group type: EXPERIMENTAL
Intervention: brief cognitive‐behavioral therapy (CBT) for suicide prevention
Number of subjects: 152
Study 32777617 — intervention group
Group type: COMPARATOR
Intervention: treatment as usual
Number of subjects: 152
Study 35977548 — intervention group
Group type: EXPERIMENTAL
Intervention: Abaloparatide 80 µg daily subcutaneous for 78 weeks
Number of subjects: 0
Study 35977548 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33873217 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical rehabilitation
Number of subjects: 211
Study 33873217 — intervention group
Group type: COMPARATOR
Intervention: Continued routine care
Number of subjects: 211
Study 35272517 — intervention group
Group type: EXPERIMENTAL
Intervention: Original recordings
Number of subjects: 186
Study 35272517 — intervention group
Group type: COMPARATOR
Intervention: Low-pass filtered versions
Number of subjects: 186
Study 34227081 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Mesenchymal Stem Cells (UC‐MSC)
Number of subjects: 24
Study 34227081 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 24
Study 32058667 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of the fourth arm of the da Vinci Si system during RAPN
Number of subjects: 58
Study 32058667 — intervention group
Group type: COMPARATOR
Intervention: Non-use of the fourth arm of the da Vinci Si system during RAPN
Number of subjects: 58
Study 36478476 — intervention group
Group type: EXPERIMENTAL
Intervention: Orismilast IR 30 mg
Number of subjects: 0
Study 36478476 — intervention group
Group type: EXPERIMENTAL
Intervention: Orismilast MR
Number of subjects: 0
Study 36478476 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33908683 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 316
Study 32863057 — intervention group
Group type: EXPERIMENTAL
Intervention: Global Pelvic Manipulation (GPM)
Number of subjects: 26
Study 32863057 — intervention group
Group type: COMPARATOR
Intervention: Sham ultrasound therapy
Number of subjects: 26
Study 34958306 — intervention group
Group type: EXPERIMENTAL
Intervention: Precision SMS text messages (stage-targeted educational information, next dose due date, site-specific walk-in hours)
Number of subjects: 956
Study 34958306 — intervention group
Group type: COMPARATOR
Intervention: Conventional SMS text messages (without educational information)
Number of subjects: 956
Study 34958306 — intervention group
Group type: EXPERIMENTAL
Intervention: Any SMS text messages (precision or conventional)
Number of subjects: 956
Study 36193880 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide (SEMA)
Number of subjects: 0
Study 36193880 — intervention group
Group type: COMPARATOR
Intervention: Dulaglutide (DULA)
Number of subjects: 0
Study 32545396 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambrotose Advanced (AA) at 2 or 4 g daily
Number of subjects: 75
Study 32545396 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambrotose LIFE (AL) at 2 or 4 g daily
Number of subjects: 75
Study 32545396 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 34757148 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuticular sutures placed 2 mm from the wound edge
Number of subjects: 50
Study 34757148 — intervention group
Group type: COMPARATOR
Intervention: Cuticular sutures placed 5 mm from the wound edge
Number of subjects: 50
Study 34075142 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine (IG)
Number of subjects: 50
Study 34075142 — intervention group
Group type: COMPARATOR
Intervention: Neutral protamine Hagedorn (NPH)
Number of subjects: 50
Study 34075644 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone
Number of subjects: 111
Study 34075644 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual buprenorphine-naloxone
Number of subjects: 111
Study 32115328 — intervention group
Group type: EXPERIMENTAL
Intervention: Anesthesiologist administered ACB (group 1)
Number of subjects: 63
Study 32115328 — intervention group
Group type: COMPARATOR
Intervention: Surgeon administered ACB (group 2)
Number of subjects: 63
Study 616357606 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous Muscle Derived Cells for Urinary Sphincter Repair (AMDCUSR) - 10 (n=5), 50 (n=2), 100 (n=4), or 200 x 10^6 (n=10) AMDCUSR in open-label studies; 150 x 10^6 AMDC-USR in RCT (n=11)
Number of subjects: 38
Study 616357606 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=6) in RCT
Number of subjects: 38
Study 33801090 — intervention group
Group type: EXPERIMENTAL
Intervention: Silymarin-enriched maize grain extract (MEg-Sm, 0.24 g Sm L‒1 of MEg)
Number of subjects: 0
Study 33801090 — intervention group
Group type: EXPERIMENTAL
Intervention: Maize grain extract (MEg, 2%)
Number of subjects: 0
Study 33801090 — intervention group
Group type: EXPERIMENTAL
Intervention: Silymarin (Sm, 0.5 mM)
Number of subjects: 0
Study 33801090 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 0
Study 34982493 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/day oral isotretinoin
Number of subjects: 26
Study 34982493 — intervention group
Group type: COMPARATOR
Intervention: Isotretinoin 0.05% gel every night
Number of subjects: 26
Study 32452161 — intervention group
Group type: EXPERIMENTAL
Intervention: Bibliotherapy (self-help materials) over 16 weeks
Number of subjects: 121
Study 32452161 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 121
Study 33120808 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramelteon (Rozerem) administered 7 days prior and 7 days post-surgery
Number of subjects: 0
Study 33120808 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 0
Study 35178367 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram for predicting cancer-specific survival (CSS) based on independent risk factors (age, surgery, stage, primary site, tumor size, histological type)
Number of subjects: 2059
Study 35178367 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram for predicting CSS
Number of subjects: 2059
Study 33148764 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA) - 1 g loading infusion followed by 125 mg/hour maintenance infusion until the end of surgery or 8 hours from incision
Number of subjects: 115
Study 33148764 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline indistinguishable from TXA)
Number of subjects: 115
Study 36610532 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose warfarin (target INR, 2.0-2.5)
Number of subjects: 401
Study 36610532 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose warfarin (target INR, 2.5-3.5)
Number of subjects: 401
Study 36610532 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose warfarin
Number of subjects: 401
Study 36610532 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose warfarin
Number of subjects: 401
Study 34108430 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenelzine
Number of subjects: 9
Study 36449420 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferiprone (15 mg/kg twice daily)
Number of subjects: 372
Study 36449420 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 372
Study 36449420 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferiprone
Number of subjects: 372
Study 34039476 — intervention group
Group type: EXPERIMENTAL
Intervention: Alloderm® (Regen)
Number of subjects: 60
Study 34039476 — intervention group
Group type: COMPARATOR
Intervention: Control (no Alloderm)
Number of subjects: 60
Study 35144034 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial scratching (ES) before embryo transfer
Number of subjects: 352
Study 35144034 — intervention group
Group type: COMPARATOR
Intervention: No endometrial scratching (ES) before embryo transfer
Number of subjects: 352
Study 35144034 — intervention group
Group type: EXPERIMENTAL
Intervention: At least one endometrial scratching (ES) before any embryo transfer
Number of subjects: 352
Study 35144034 — intervention group
Group type: COMPARATOR
Intervention: No endometrial scratching (ES) before any embryo transfer
Number of subjects: 352
Study 33578001 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (SRS) administered ≤4 weeks postoperatively
Number of subjects: 133
Study 33578001 — intervention group
Group type: COMPARATOR
Intervention: Stereotactic radiosurgery (SRS) administered >4 weeks postoperatively
Number of subjects: 133
Study 33578001 — intervention group
Group type: COMPARATOR
Intervention: Delayed SRS
Number of subjects: 133
Study 33578001 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (SRS)
Number of subjects: 133
Study 34893535 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-year lifestyle intervention
Number of subjects: 160
Study 34893535 — intervention group
Group type: COMPARATOR
Intervention: usual care
Number of subjects: 160
Study 32824040 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive LBP intervention module based on the Back School Program
Number of subjects: 284
Study 32824040 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 284
Study 34887234 — intervention group
Group type: EXPERIMENTAL
Intervention: Intentionally treated water
Number of subjects: 2
Study 35305796 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportion of classmates receiving private tutoring
Number of subjects: 0
Study 35305796 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher proportion of classmates receiving private tutoring
Number of subjects: 0
Study 35305796 — intervention group
Group type: EXPERIMENTAL
Intervention: Test-related stress as a mechanism
Number of subjects: 0
Study 32152170 — intervention group
Group type: EXPERIMENTAL
Intervention: CBD 20 mg/kg/day
Number of subjects: 10
Study 32152170 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 34157385 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent plasma
Number of subjects: 0
Study 32272334 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived cognitive impairment
Number of subjects: 123
Study 32272334 — intervention group
Group type: EXPERIMENTAL
Intervention: Disability measures
Number of subjects: 123
Study 35279770 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment Program for Children with Aggressive Behavior (THAV)
Number of subjects: 76
Study 35279770 — intervention group
Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 76
Study 33663558 — intervention group
Group type: EXPERIMENTAL
Intervention: WeChat-based educational intervention (12-week duration, consisting of four individual online educational sessions and online educational materials)
Number of subjects: 118
Study 33663558 — intervention group
Group type: EXPERIMENTAL
Intervention: WeChat-based educational intervention
Number of subjects: 118
Study 33663558 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 118